Samuel Forrester Hunter MD PhD
Neuroimaging, Neuroimmunology/Multiple Sclerosis, Neurophysiology, Neuro-Ophthalmology
President, Advanced Neurosciences Institute
Join to View Full Profile
150 Stephen P Yokich PkwySuite HSpring Hill, TN 37174
Phone+1 615-791-5470
Fax+1 615-595-0265
Dr. Hunter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and ScienceFellowship, Clinician Investigator Training Program, 1995 - 1997- Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1992 - 1995
- Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 1991 - 1992
University of Texas Medical Branch GalvestonPhD, Pharmacology-Toxicology, 1984 - 1991
University of Texas Medical Branch School of MedicineClass of 1991- University of Helsinkipostgraduate, Pharmacology/Physiology, ITT International Fellow/Flubright Award, 1983 - 1984
- Oral Roberts UniversityBS, Biology, Computer Science, Mathematics, Chemistry, Summa Cum Laude, 1979 - 1983
Certifications & Licensure
TN State Medical License 1997 - 2025
FL State Medical License 2015 - 2017
TX State Medical License 1993 - 1998
MN State Medical License 1992 - 1997
American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
- Immunodeficiency in MS Start of enrollment: 2020 Jun 29
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 study.Samuel F Hunter, John W Lindsey, Benjamin Osborne, Bethany Schreiber, Filipe Branco
Multiple Sclerosis and Related Disorders. 2024-11-01 - Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study.James D Bowen, Jessica Stulc, Samuel F Hunter, Hailu Chen, James B Lewin
Advances in Therapy. 2024-08-01 - 2 citationsThalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting m...Robert Zivadinov, Niels Bergsland, Dejan Jakimovski, Bianca Weinstock-Guttman, Lorena Lorefice
Neuroimage. Clinical. 2024-01-01
Press Mentions
Preparing for #ACTRIMS2017 – Top 3 Topics from ACTRIMS 2016April 26th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
